000163930 001__ 163930
000163930 005__ 20240229123201.0
000163930 0247_ $$2doi$$a10.1007/s11060-020-03640-3
000163930 0247_ $$2pmid$$apmid:33026636
000163930 0247_ $$2ISSN$$a0167-594X
000163930 0247_ $$2ISSN$$a1573-7373
000163930 0247_ $$2altmetric$$aaltmetric:93203475
000163930 037__ $$aDKFZ-2020-02154
000163930 041__ $$aeng
000163930 082__ $$a610
000163930 1001_ $$0P:(DE-He78)a23e88cc676489fe05be8c178ceaf58e$$aSelt, Florian$$b0$$eFirst author$$udkfz
000163930 245__ $$aResponse to trametinib treatment in progressive pediatric low-grade glioma patients.
000163930 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V$$c2020
000163930 3367_ $$2DRIVER$$aarticle
000163930 3367_ $$2DataCite$$aOutput Types/Journal article
000163930 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1609155770_26462
000163930 3367_ $$2BibTeX$$aARTICLE
000163930 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163930 3367_ $$00$$2EndNote$$aJournal Article
000163930 500__ $$a#EA:B310#LA:B310# 2020 Sep;149(3):499-510
000163930 520__ $$aA hallmark of pediatric low-grade glioma (pLGG) is aberrant signaling of the mitogen activated protein kinase (MAPK) pathway. Hence, inhibition of MAPK signaling using small molecule inhibitors such as MEK inhibitors (MEKi) may be a promising strategy.In this multi-center retrospective centrally reviewed study, we analyzed 18 patients treated with the MEKi trametinib for progressive pLGG as an individual treatment decision between 2015 and 2019. We have investigated radiological response as per central radiology review, molecular classification and investigator observed toxicity.We observed 6 partial responses (PR), 2 minor responses (MR), and 10 stable diseases (SD) as best overall responses. Disease control rate (DCR) was 100% under therapy. Responses were observed in KIAA1549:BRAF- as well as neurofibromatosis type 1 (NF1)-driven tumors. Median treatment time was 12.5 months (range: 2 to 27 months). Progressive disease was observed in three patients after cessation of trametinib treatment within a median time of 3 (2-4) months. Therapy related adverse events occurred in 16/18 patients (89%). Eight of 18 patients (44%) experienced severe adverse events (CTCAE III and/or IV; most commonly skin rash and paronychia) requiring dose reduction in 6/18 patients (33%), and discontinuation of treatment in 2/18 patients (11%).Trametinib was an active and feasible treatment for progressive pLGG leading to disease control in all patients. However, treatment related toxicity interfered with treatment in individual patients, and disease control after MEKi withdrawal was not sustained in a fraction of patients. Our data support in-class efficacy of MEKi in pLGGs and necessity for upfront randomized testing of trametinib against current standard chemotherapy regimens.
000163930 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000163930 588__ $$aDataset connected to CrossRef, PubMed,
000163930 7001_ $$0P:(DE-He78)a6b5fcabf661bef95109dbee87dc5271$$avan Tilburg, Cornelis M$$b1$$udkfz
000163930 7001_ $$aBison, Brigitte$$b2
000163930 7001_ $$0P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6$$aSievers, Philipp$$b3$$udkfz
000163930 7001_ $$aHarting, Inga$$b4
000163930 7001_ $$0P:(DE-He78)3de637452ba900e2bdd359b8f41953bf$$aEcker, Jonas$$b5$$udkfz
000163930 7001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian W$$b6$$udkfz
000163930 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b7$$udkfz
000163930 7001_ $$aBahr, Annabelle$$b8
000163930 7001_ $$aSimon, Michèle$$b9
000163930 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David T W$$b10$$udkfz
000163930 7001_ $$aWell, Lennart$$b11
000163930 7001_ $$aMautner, Victor-Felix$$b12
000163930 7001_ $$0P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aCapper, David$$b13$$udkfz
000163930 7001_ $$aHernáiz Driever, Pablo$$b14
000163930 7001_ $$aGnekow, Astrid$$b15
000163930 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan M$$b16$$udkfz
000163930 7001_ $$0P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aWitt, Olaf$$b17$$udkfz
000163930 7001_ $$0P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aMilde, Till$$b18$$eLast author$$udkfz
000163930 773__ $$0PERI:(DE-600)2007293-4$$a10.1007/s11060-020-03640-3$$n3$$p499-510$$tJournal of neuro-oncology$$v149$$x1573-7373$$y2020
000163930 909CO $$ooai:inrepo02.dkfz.de:163930$$pVDB
000163930 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a23e88cc676489fe05be8c178ceaf58e$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000163930 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a6b5fcabf661bef95109dbee87dc5271$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000163930 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000163930 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3de637452ba900e2bdd359b8f41953bf$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000163930 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000163930 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000163930 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000163930 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000163930 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000163930 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000163930 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000163930 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000163930 9141_ $$y2020
000163930 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2020-02-27$$wger
000163930 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2020-02-27$$wger
000163930 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-02-27
000163930 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-02-27
000163930 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-02-27
000163930 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-02-27
000163930 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-02-27
000163930 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index$$d2020-02-27
000163930 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-02-27
000163930 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-02-27
000163930 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-02-27
000163930 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEURO-ONCOL : 2018$$d2020-02-27
000163930 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-02-27
000163930 9201_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x0
000163930 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000163930 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x2
000163930 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x3
000163930 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lPediatric Glioma$$x4
000163930 9201_ $$0I:(DE-He78)BE01-20160331$$kBE01$$lDKTK BE zentral$$x5
000163930 980__ $$ajournal
000163930 980__ $$aVDB
000163930 980__ $$aI:(DE-He78)B310-20160331
000163930 980__ $$aI:(DE-He78)HD01-20160331
000163930 980__ $$aI:(DE-He78)B300-20160331
000163930 980__ $$aI:(DE-He78)B062-20160331
000163930 980__ $$aI:(DE-He78)B360-20160331
000163930 980__ $$aI:(DE-He78)BE01-20160331
000163930 980__ $$aUNRESTRICTED